Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVXV BiondVax Pharmaceuticals		$1.36	$1.25 ▼ $11.80	$2.54M	2.37	127,289 shs	23,000 shs
CDTX Cidara Therapeutics	$0.72	$0.78	$0.59 ▼ $1.48	$65.43M	0.98	657,627 shs	273,204 shs
ONVO Organovo	$1.15 +2.7%	$1.04	$0.89 ▼ $2.23	$11.55M	0.91	863,510 shs	578,990 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVXV BiondVax Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-36.45%
CDTX Cidara Therapeutics	-0.03%	-16.44%	+1.09%	+0.87%	-35.54%
ONVO Organovo	+2.68%	+10.58%	+9.52%	+15.00%	-47.49%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.7955 of 5 stars	3.5	3.0	0.0	4.6	3.0	0.8	0.0
ONVO Organovo	0.4569 of 5 stars	0.0	3.0	0.0	0.0	2.9	0.0	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.00	Buy	$4.67	546.35% Upside
ONVO Organovo	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ONVO, CDTX, and BVXV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/8/2024	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	($3.81) per share	N/A
CDTX Cidara Therapeutics	$64.29M	1.02	N/A	N/A	($0.04) per share	-18.05
ONVO Organovo	$370K	31.21	N/A	N/A	$1.76 per share	0.65

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVXV BiondVax Pharmaceuticals	-$5.80M	-$2.55	N/A	N/A	N/A	N/A	-346.36%	-29.52%	N/A
CDTX Cidara Therapeutics	-$29.80M	-$0.39	N/A	N/A	N/A	-55.49%	-264.84%	-48.12%	5/9/2024 (Estimated)
ONVO Organovo	-$17.26M	-$2.17	N/A	N/A	N/A	N/A	-182.88%	-138.52%	7/11/2024 (Estimated)

Latest ONVO, CDTX, and BVXV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/8/2024	Q3 2024	ONVO Organovo	-$0.41	-$0.40	+$0.01	-$0.40	$0.08 million	$0.01 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
ONVO Organovo	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVXV BiondVax Pharmaceuticals	N/A	4.12	4.12
CDTX Cidara Therapeutics	N/A	1.62	1.55
ONVO Organovo	N/A	3.67	3.67

Ownership

Institutional Ownership

Company	Institutional Ownership
BVXV BiondVax Pharmaceuticals	11.83%
CDTX Cidara Therapeutics	35.82%
ONVO Organovo	8.23%

Insider Ownership

Company	Insider Ownership
BVXV BiondVax Pharmaceuticals	6.03%
CDTX Cidara Therapeutics	7.43%
ONVO Organovo	4.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BVXV BiondVax Pharmaceuticals	33	1.87 million	1.76 million	Not Optionable
CDTX Cidara Therapeutics	73	90.62 million	83.89 million	Optionable
ONVO Organovo	18	10.04 million	9.64 million	Optionable

ONVO, CDTX, and BVXV Headlines

Source	Headline
	Organovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.com americanbankingnews.com - April 18 at 2:24 AM
	Organovo's drug significantly reduces liver fat in NASH study health.economictimes.indiatimes.com - April 16 at 9:35 AM
	Why Organovo Stock Is Up Today msn.com - April 15 at 2:40 PM
	Organovo’s fatty liver disease drug meets main goal in mid-stage study kfgo.com - April 15 at 9:40 AM
	Organovo's fatty liver disease drug meets main goal in mid-stage study reuters.com - April 15 at 8:28 AM
	Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo globenewswire.com - April 15 at 8:05 AM
	StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO) americanbankingnews.com - April 10 at 2:18 AM
	Organovo files patent for farnesoid x receptor agonist compound for treating diseases pharmaceutical-technology.com - March 24 at 6:42 PM
	Organovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning Calls benzinga.com - February 24 at 7:35 AM
	Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - February 10 at 2:25 PM
	Organovo Holdings Inc ONVO morningstar.com - February 9 at 7:39 PM
	ONVO Continues Progress finance.yahoo.com - February 9 at 2:38 PM
	Organovo: Fiscal Q3 Earnings Snapshot sfgate.com - February 8 at 7:40 PM
	Organovo Holdings Unveils Corporate Presentation Online msn.com - February 8 at 9:38 AM
	Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress finance.yahoo.com - January 25 at 12:43 PM
	Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress finance.yahoo.com - January 9 at 9:33 AM
	ONVO Shares Experience Surge in Value knoxdaily.com - January 4 at 10:15 AM
	Checking in on Organovo Holdings Inc (ONVO) after recent insiders movement knoxdaily.com - January 1 at 6:27 PM
	Organovo Holdings: Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibits cbonds.com - December 30 at 8:48 AM
	Organovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results finanznachrichten.de - December 7 at 8:37 AM
	Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results finance.yahoo.com - December 6 at 9:16 AM
	OVNO Continues Developing Breakthrough Treatments msn.com - November 13 at 4:20 PM
	CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan finance.yahoo.com - November 13 at 8:43 AM
	Organovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023) finance.yahoo.com - November 11 at 9:02 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BiondVax Pharmaceuticals

NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Cidara Therapeutics

NASDAQ:CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Organovo

NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial